| WB | 1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 1/25 | Human,Mouse,Rat |
| FCM | 1/25 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Alpha-2-HS-glycoprotein, Alpha-2-Z-globulin, Ba-alpha-2-glycoprotein, Fetuin-A, Alpha-2-HS-glycoprotein chain A, Alpha-2-HS-glycoprotein chain B, AHSG, FETUA |
| Entrez GeneID | 197 |
| WB Predicted band size | 39.4kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This AHSG antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 247-276 amino acids from the C-terminal region of human AHSG. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于AHSG(Alpha-2-HS-glycoprotein，胎球蛋白A)抗体的3篇参考文献及简要摘要内容：
1. **文献名称**: *"Fetuin-A (AHSG) as a biomarker for cardiovascular disease and therapeutic target in chronic kidney disease"*
**作者**: Jahnen-Dechent W, et al.
**摘要**: 该研究探讨了AHSG(胎球蛋白A)在心血管疾病和慢性肾病中的生物标志物作用。作者发现，AHSG抗体可用于检测血清中胎球蛋白A的水平，其浓度与动脉钙化和肾功能损伤密切相关，提示其在疾病诊断和预后评估中的潜在价值。
2. **文献名称**: *"Role of fetuin-A in insulin resistance and type 2 diabetes mellitus"*
**作者**: Ix JH, et al.
**摘要**: 研究利用AHSG抗体分析胎球蛋白A在胰岛素抵抗中的作用。结果表明，AHSG通过抑制胰岛素受体信号通路加重代谢紊乱，其抗体检测可用于评估2型糖尿病患者的炎症和代谢状态，为靶向治疗提供依据。
3. **文献名称**: *"AHSG modulates tumor progression by regulating macrophage polarization via antibody-mediated pathways"*
**作者**: Wang H, et al.
**摘要**: 本文通过AHSG抗体研究胎球蛋白A在肿瘤微环境中的作用。研究发现，AHSG抗体可阻断胎球蛋白A与巨噬细胞的相互作用，抑制促肿瘤M2型巨噬细胞极化，从而减缓肿瘤生长和转移。
4. **文献名称**: *"Fetuin-A as a mediator of hepatic steatosis and mitochondrial dysfunction in non-alcoholic fatty liver disease"*
**作者**: Mathews S, et al.
**摘要**: 该研究利用AHSG抗体检测非酒精性脂肪肝(NAFLD)患者肝组织中胎球蛋白A的表达。结果显示，AHSG通过促进脂质积累和线粒体功能障碍加剧肝损伤，其抗体可能成为干预NAFLD病理过程的潜在工具。
以上文献涵盖了AHSG抗体在代谢疾病、肿瘤、心血管及肝病研究中的应用，均聚焦于其作为检测工具或治疗靶点的机制探索。
**Background of AHSG Antibodies**
AHSG (alpha-2-HS-glycoprotein), also known as fetuin-A, is a multifunctional glycoprotein primarily synthesized in the liver and secreted into the bloodstream. It plays critical roles in regulating mineral metabolism, inflammation, and insulin signaling, while also acting as a carrier protein for bioactive molecules. AHSG is implicated in pathological conditions such as chronic kidney disease, cardiovascular calcification, metabolic syndrome, and cancer, making it a subject of biomedical research.
AHSG antibodies are immunological tools designed to detect, quantify, or inhibit AHSG in experimental and clinical settings. These antibodies are widely used in techniques like Western blotting, ELISA, and immunohistochemistry to study AHSG expression, localization, and interaction partners in tissues or biological fluids. Monoclonal antibodies offer high specificity for targeted epitopes, whereas polyclonal antibodies provide broader detection of AHSG's conformational variants.
Research utilizing AHSG antibodies has highlighted its dual role as both a promoter and inhibitor of pathological calcification, depending on context, and its involvement in modulating immune responses. Therapeutic potential is being explored, particularly in diseases linked to ectopic calcification or chronic inflammation. However, challenges remain, including cross-reactivity with homologous proteins and variability due to AHSG's post-translational modifications.
Overall, AHSG antibodies are vital for unraveling the protein's complex functions and advancing diagnostic or therapeutic strategies for related disorders.
×
